Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
durvalumab + gemcitabine + cisplatin + nab-paclitaxel
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Durvalumab + gemcitabine + cisplatin + nab-paclitaxel is a combination chemo-immunotherapy regimen being investigated as a neoadjuvant treatment for resectable biliary tract cancer (BTC). Durvalumab is a human monoclonal antibody that targets programmed death-ligand 1 (PD-L1), preventing its interaction with PD-1 and CD80 to enhance T-cell mediated anti-tumor activity. Gemcitabine and cisplatin are standard cytotoxic agents that inhibit DNA synthesis and cause DNA cross-linking, respectively. Nab-paclitaxel is an albumin-bound nanoparticle formulation of paclitaxel that stabilizes microtubules, leading to cell cycle arrest. This specific four-drug regimen is being evaluated in a Phase II trial led by Tianjin Medical University Cancer Institute and Hospital to improve surgical outcomes and survival in patients with operable BTC, building upon the established efficacy of durvalumab combinations in the metastatic setting.
- Other names
- MEDI-4736MEDI4736MEDI 4736albumin-bound paclitaxel
02
Targets
DNACD274 (Programmed cell death protein 1 ligand 1)RNR (Ribonucleotide reductase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on durvalumab + gemcitabine + cisplatin + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on durvalumab + gemcitabine + cisplatin + nab-paclitaxel.